

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 06/02/2018

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
Azilect	EMEA/H/C/574/IAin/75/G	N04BD02	rasagiline	Teva B.V.	16-dic-16	20-dic-17	26-gen-18	12-feb-18	036983082	8
Azilect	EMEA/H/C/574/IAin/75/G	N04BD02	rasagiline	Teva B.V.	16-dic-16	20-dic-17	26-gen-18	12-feb-18	036983094	9
Azilect	EMEA/H/C/574/IAin/75/G	N04BD02	rasagiline	Teva B.V.	16-dic-16	20-dic-17	26-gen-18	12-feb-18	036983106	10
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271115	12
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271127	13
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	04127139	14
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271141	15
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271154	16
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271166	17
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271178	18
Esbriet	EMEA/H/C/2154/IB/46/G	L04AX05	Pirfenidone	Roche Registration Limited	26-giu-17	08-dic-17	26-gen-18	12-feb-18	041271180	19
Humira	EMEA/H/C/481/X/164	L04AB04	Adalimumab	AbbVie Ltd	12-ott-17	08-dic-17	26-gen-18	12-feb-18	035946211	22
Mysimba	EMEA/H/C/3687/IB/21	A08AA62	naltrexone / bupropion	Orexigen Therapeutics Ireland Limited	21-set-17	08-dic-17	26-gen-18	12-feb-18	044014025	2
OCALIVA	EMEA/H/C/4093/IB/1/G	A05AA04	acido obeticolico	Intercept Pharma Ltd	21-apr-17	01-dic-17	26-gen-18	12-feb-18	045222039	3
OCALIVA	EMEA/H/C/4093/IB/1/G	A05AA04	acido obeticolico	Intercept Pharma Ltd	21-apr-17	01-dic-17	26-gen-18	12-feb-18	045222041	4
Oncaspar	EMEA/H/C/3789/X/8	L01XX24	pegaspargase	Baxalta Innovations GmbH	12-ott-17	08-dic-17	26-gen-18	12-feb-18	044702025	2
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865019	1
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865021	2
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865033	3
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865045	4
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865058	5
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865060	6
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865072	7
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865084	8
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865096	9
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865108	10
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865110	11
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865122	12
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865134	13
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865146	14
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865159	15
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865161	16
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865173	17
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865185	18
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865197	19
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865209	20
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865211	21
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865223	22
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865235	23
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865247	24
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865250	25
Tacforius	EMEA/H/C/4435	L04AD02	tacrolimus	Teva B.V.	12-ott-17	08-dic-17	26-gen-18	12-feb-18	045865262	26
Truberzi	EMEA/H/C/4098/IB/2/G	Pending	eluxadolone	Allergan Pharmaceuticals International Limited	31-gen-17	08-dic-17	26-gen-18	12-feb-18	045077056	5
Truberzi	EMEA/H/C/4098/IB/2/G	Pending	eluxadolone	Allergan Pharmaceuticals International Limited	31-gen-17	08-dic-17	26-gen-18	12-feb-18	045077068	6

La responsabilità di qualsiasi onere e/o attività che l'Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all'immissione in commercio del medicinale, è totalmente a carico dell'Azienda stessa. L'ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.